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ABSTRACT
Anal incontinence is a devastating condition that signiﬁcantly reduces the quality of life. Our aim
was to evaluate the effect of human adipose stem cell (hASC) injections in a rat model for anal
sphincter injury, which is the main cause of anal incontinence in humans. Furthermore, we tested
if the efﬁcacy of hASCs could be improved by combining them with polyacrylamide hydrogel car-
rier, Bulkamid. Human ASCs derived from a female donor were culture expanded in DMEM/F12
supplemented with human platelet lysate. Female virgin Sprague-Dawley rats were randomized
into four groups (n5 14–15/group): hASCs in saline or Bulkamid (3 3 105/60 ll) and saline or Bul-
kamid without cells. Anorectal manometry (ARM) was performed before anal sphincter injury, at
two (n5 58) and at four weeks after (n5 33). Additionally, the anal sphincter tissue was examined
by micro-computed tomography (lCT) and the histological parameters were compared between
the groups. The median resting and peak pressure during spontaneous contraction measured by
ARM were signiﬁcantly higher in hASC treatment groups compared with the control groups with-
out hASCs. There was no statistical difference in functional results between the hASC-carrier
groups (saline vs. Bulkamid). No difference was detected in the sphincter muscle continuation
between the groups in the histology and lCT analysis. More inﬂammation was discovered in the
group receiving saline with hASC. The hASC injection therapy with both saline and Bulkamid is a
promising nonsurgical treatment for acute anal sphincter injury. Traditional histology combined
with the 3D lCT image data lends greater conﬁdence in assessing muscle healing and continuity.
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SIGNIFICANCE STATEMENT
The increasing awareness of good quality of life sets demands for better and less invasive treat-
ment methods of the pelvic floor disorders, for example, anal incontinence. Human adipose
stem cells (hASCs) are readily available, easily obtained, have low immunogenicity and high mul-
tilineage differentiation and are, therefore, an ideal cell source. In this study, an animal model
was used to develop a mini-invasive injection treatment method using hASCs. The functional
measurements showed significant improvement in hASC-treatment groups compared with the
controls. A biocompatible carrier polyacrylamide hydrogel Bulkamid was found to be a suitable
carrier for the stem cells, and a novel method of micro-computed tomography was found useful
for targeting the histological slides.
INTRODUCTION
Anal incontinence (AI) is a devastating condition
that signiﬁcantly reduces the quality of life. Espe-
cially in women, the fecal incontinence symptoms
cause depression, embarrassment and lifestyle
changes that have a negative effect their everyday
life [1]. The primary management of AI is conserv-
ative treatment including dietary, medical, and
psychological interventions, as well as physiother-
apy. A common operation for persistent AI has
been secondary sphincteroplasty which may not
have the desired long-term results, especially with
denervated sphincters [2]. Sacral nerve modula-
tion and transcutaneous posterior tibial neuromo-
dulation have increasingly been used for fecal
incontinence. However, the cure rates vary
depending on the outcome measure in use with
long-term results reaching up to 54% for sacral
neuromodulation [3, 4]. Surgical methods often
carry a risk of complications and are both
demanding and expensive.
AI is deﬁned as an involuntary loss of ﬂatus,
liquid, or solid stool that is a social or hygienic
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ENABLING TECHNOLOGIES FOR CELL-BASED CLINICAL
TRANSLATION
problem [5]. There are different estimates of the incidence of AI
varying from 3% to over 40% in the adult population, depending
on the deﬁnition and study population [6–8]. In women, obstetric
injury is one of the main causes of AI, although its etiology is often
multifactorial [9].
There are several studies concerning stem cells in the treat-
ment of anal sphincter defects. Rat models with muscle-derived
stem cells or myoblasts as the stem cell origin are the most com-
mon study designs [10–14], although bigger animals (rabbits,
dogs) have been used as well [15, 16]. Mesenchymal stem cells
(MSC) derived from bone marrow have been used in a few studies
and the results are promising [17–19]. Additionally, a small clinical
trial with human adipose stem cells (hASCs) has recently been
published [20].
Human ASCs are easily obtained, and their features include
low immunogenicity and high multilineage differentiation capabil-
ity [21]. The ASCs have shown to differentiate into muscle cells
[22, 23]. Human ASCs have also demonstrated paracrine func-
tion—immunomodulation, cytokine secretion, cytoprotection,
and neovascularization [21, 24, 25]. Therefore, ASCs are an attrac-
tive source of cell material for regenerative medicine and tissue
engineering to rehabilitate impaired organ function. However,
there is a need for optimal carrier material to provide a favorable
environment for ASCs’ paracrine actions. Bulkamid is a nondegrad-
able viscoelastic water-based polymer and it is mainly used for
injection therapy of female urinary incontinence [26, 27]. It has
also been used for AI [28]. Other bulking agents, such as bovine
collagen, have been tested but the results are transient [29, 30].
The purpose of our study was to develop a novel, mini-
invasive, and effective treatment method utilizing hASCs com-
bined with either saline (0.9% NaCl) or polyacrylamide hydrogel
(Bulkamid) to cure AI due to acute anal sphincter trauma. To facili-
tate clinical translation, cells of human origin were used and
hASCs were isolated and expanded in clinically viable conditions
using human platelet lysate as a culture medium supplement
instead of fetal bovine serum. This is, to our knowledge, the ﬁrst
study to use Bulkamid as a stem cell carrier, to study in vivo the
hASCs in an animal functional model and to use micro-computed
tomography (lCT) as a tool to view the treated anal sphincter
area.
MATERIALS AND METHODS
The animal study protocol was approved by the Regional State
Administrative Agency (AVI/Ella no ESAVI/2828/04.10.07/2015).
Adipose tissue sample was obtained under the approval of the
Ethics Committee of the Pirkanmaa Hospital District (Tampere,
Finland, R15161). The hASCs were isolated from adipose tissue
sample from a female donor undergoing elective plastic surgery at
Tampere University Hospital (Tampere, Finland) with the patient’s
written consent. The ﬁnal study was designed after a pilot study
of 24 Sprague-Dawley rats (results not included in the analysis). In
the pilot study, the rat anorectal manometry (ARM) technique,
anal sphincter cutting and repairing, the injection technique, the
suitable amount of the gel, and the amount of stem cells per injec-
tion were tested. The cell amounts of 5 3 105/100 ml and 5 3
106/100 ml were compared, and the lower cell count was chosen
due to better cell viability before injection.
Treatment Protocol
Sixty (60) Sprague-Dawley female virgin rats (Janvier Laboratoires),
weight 220–300 g, age 14 weeks were randomly selected, then
anesthetized with intraperitoneal injections of medetomidine
0.25 mg/kg and ketamine 32.5 mg/kg, and buprenorﬁn 0.05 mg/
kg s.c. and carprofen 5 mg/kg s.c. were used for postoperative
pain. After the anal manometry and the sphincter operation, the
anesthesia was reversed using atipamezole 1 mg/kg.
The ARM was performed using Polygraf ID manometry system
with ERCP manometry triple lumen catheters (Medtronic, Poly-
gram NET, computer unit Windows XP, Minneapolis, MN, USA).
The measurements were conducted preoperatively and at 2 and 4
weeks after the operation. (Fig. 1, Supporting Information Fig. S1).
Sprague-Dawley rats, n = 60 
0.9%NaCl+hASC, n = 15 Bulkamid+hASC, n = 14 0.9%NaCl, n = 16* Bulkamid, n = 15 
Anorectal manometry (ARM) sphincterotomy and repair, injecon therapy 
ARM at 2 weeks 
Euthanized at 
2 weeks, n = 7 
μCT, histology 
Euthanized at  
2 weeks, n = 6 
μCT, histology 
Euthanized at 
2 weeks, n = 6 
μCT, histology 
ARM at 4 weeks 
Euthanized at 
4 weeks, n = 8 
μCT, histology 
Euthanized at 
4 weeks, n = 8 
μCT, histology 
Euthanized at 
4 weeks, n = 8
μCT, histology 
Euthanized at 
2 weeks, n = 6 
μCT, histology 
Euthanized at 4 
weeks, n = 9
μCT, histology 
Figure 1. Flow chart of the study protocol. *2 rats died presumably due to anesthesia complication. Abbreviations: hASCs, human adipose
stem cells; lCT, micro-computed tomography; NaCl, sodium chloride.
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The duration of ARM procedure was approximately 30 minutes,
during which resting anal sphincter pressures and peak pressures
during spontaneous contraction were measured (resting pressure
3–7 times [mean 5.64] and contraction pressure 7–12 times
[mean 10.4]). Mean values of these measurements were used in
further analysis.
The sphincter was cut from all animals to mimic an acute
fourth grade anal sphincter tear (injury of the external and inter-
nal sphincter muscle and anal mucosa) and sewed back with 6-0
poliglecaprone (Ethicon, Johnson & Johnson, Monocryl, Somer-
ville, NJ, USA) continuous stiches utilizing magnifying loupes. First,
the anal mucosa and internal sphincter were repaired, and then,
the injections were delivered after which the perineal skin was
closed.
The rats were divided into four groups for the injections: injec-
tion of 3 3 105 hASCs in saline (0.9% NaCl) solution (n5 15),
hASCs in 2.5% polyacrylamide hydrogel (Bulkamid, Contura Inter-
national A/S, Denmark) (n5 15). The control groups consisted of
rats with only saline (n5 16, two died within the ﬁrst postopera-
tive day presumably because of anesthetic reaction and were
excluded from the analysis) and polyacrylamide hydrogel injec-
tions (n5 14). There were two injections with a 25-gauge needle
on both ends of the external sphincter (degrees 308 and 3308 on
superimposed clock face, Supporting Information Fig. S3); the
total injection volume of the four injections being 60 ll per animal
for all Bulkamid and 0.9% NaCl-groups.
The rats were again anesthetized for the anal manometry con-
trol with medetomidine and ketamine combination as described
above. After the last anal manometry examination, the rats were
euthanized using carbon monoxide. The anal manometry results
were analyzed by a blinded researcher (HT) to exclude observer
bias.
ASC Isolation, Cell Culture, Cell Viability, and Phenotype
The hASCs were isolated as previously described [31]. The hASCs
were expanded in DMEM/F12 (1:1) (Thermo Fisher Scientiﬁc Inc.,
Carlsbad, CA, USA, https://www.thermoﬁsher.com) supplemented
with 5% Pooled Human Platelet Lysate (Stemulate; Cook General
Bio-Technology, Indianapolis, IN, USA, http://cookregenterec.
com), 1% antibiotics (100 U/ml penicillin and 0,1 mg/ml strepto-
mycin; Thermo Fisher Scientiﬁc Inc.), and 1% L-glutamine (Thermo
Fisher Scientiﬁc Inc, GlutaMAX-100, Indianapolis, IN, USA). The
medium was changed twice a week, and the cells were divided
upon reaching conﬂuency. The cells were detached using TrypLE
Select (Thermo Fisher Scientiﬁc Inc., Carlsbad, CA, USA). From 4 to
5 days prior to cell injections, the ASCs were labeled with 200 mg/
ml magnetizable nanoparticles (PMP-50; Kisker Biotech GmbH &
Co., Steinfurt, Germany, https://kisker-biotech.com) for 48 hours
for cell detection. For cell injections, 5 3 105 hASCs (passage
between 4 to 7) were blended with 100 ml of 0.9% NaCl (Baxter
Healthcare SA, Zurich, Switzerland, http://Baxter.com) or Bulkamid
hydrogel (Contura International A/S, Soeborg, Denmark, https://
bulkamid.com).
For the cell viability, 5 3 105 hACSs were blended with 100 ml
Bulkamid, incubated at room temperature for 3 hours (the maxi-
mum delay between the cell preparation and the injections), and
the cell viability was assessed with LIVE/DEAD Viability/Cytotoxicity
kit for mammalian cells (Thermo Fisher Scientiﬁc Inc., Carlsbad, CA,
USA). The hASCs in Bulkamid were stained with 1 mM Calcein AM
and 0.8 mM Ethidium homodimer-1 (EthD-1) for 45 minutes.
Fluorescence pictures were taken with Fluorescence Microscope
(Olympus. IX51S18F-2 and camera DP71, Japan).
The phenotype of the hASCs was assessed with
ﬂuorescence-activated cell sorter (BD Biosciences, Franklin Lakes,
NJ, USA, https://www.bdbiosciences.com. BD FACSAria Fusion
Cell Sorter) at passage 7. Monoclonal antibodies against CD14-
phycoerythrincyanine (PE-Cy7), CD19-PE-Cy7, CD45RO-allophyco-
cyanin (APC), CD54-Fluorescein isothiocyanate (FITC), CD73-
phycoerythrin (PE), CD90-APC (BD Biosciences, Franklin Lakes,
NJ, USA), CD105-PE (R&D Systems Inc., Minneapolis, MN, USA,
http://www.rndsystems.com), CD34-APC and HLA-DR-PE (Immu-
notools GmbH, Friesoythe, Germany, http://www.immunotools.
de) were used. According to the International Society for Cellular
Therapy standard criteria, cells positive for CD73, CD90 and
CD105 but negative for CD14, CD34, CD45, and HLA-DR are con-
sidered as MSCs [32, 33].
lCT Imaging
The analysis of the anal sphincter was performed after sacriﬁcing
the animals. The excised samples were imaged in a lCT instru-
ment (Xradia MicroXCT-400, Carl Zeiss, Pleasanton, CA, USA). To
increase the contrast between the soft tissues, the samples were
put through a staining regimen. The tissue samples were stored in
4% paraformaldehyde (PFA)-solution (Sigma). The PFA was then
changed to 70% ethanol solution, then to 95% ethanol, 99.5%
ethanol, and 10 mg/ml iodine in ethanol. The samples were trans-
ferred into sample holders and were kept at room temperature
for a minimum of 24 hours prior to imaging in order to avoid
imaging artifacts resulting from thermal expansion of the tissue
samples. The imaging parameters for all 58 samples were constant
(Table 1). After imaging, the samples were transferred into a 70%
ethanol solution for storage and following histological analyses.
Tomographic three-dimensional (3D) image reconstruction was
performed with proprietary software installed in the instrument
(Carl Zeiss, Xradia XMReconstructor, Pleasanton, CA, USA). The
reconstructed image volume was imported into AVIZO image
processing software (FEI Company, Hillsboro, OR, USA) for image
processing and inspection. The anal sphincter complex was visual-
ized through 3D volume rendering. It was used in combination
with tomographic data exploration as freely selectable two-
dimensional (2D) views of the 3D dataset to conﬁrm the histologi-
cal assessment of muscle continuity. Additionally, it was used to
visualize in 3D the entire sample instead of selected 2D sections
as in histology and to monitor the presence of any detectable
PMP-50 labeled cells.
Table 1. Technical details about the micro-computed tomography
imaging
Voltage 60 kV
Current 166 mA
Source distance 58 mm
Detector distance 170 mm
Exposure time 4 seconds
Imaging time 2.5 hours
Pixel size 17.0354 mm
Image volume dimensions 10003 10003 1000 pixels
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Histology
The formalin ﬁxed, parafﬁn embedded tissues were sectioned (4
mm) and stained with Hematoxylin & Eosin (HE) for morphological
interpretation. Furthermore, picrosirius red staining was used to
demonstrate collagen and Perls Prussian blue to demonstrate the
presence of iron from tissue sections. Immunohistochemistry using
anti-human Vimentin 1:200 (Clone:BS13, BSH-7100, Nordic Biosite,
T€aby, Sweden) and STEM121 1:500 (Clone: Stem121, Y40410,
Takara Bio Inc., Shiga, Japan) antibodies was performed to detect
hASCs from rat tissue sections. Smooth muscle actin antibody
1:200 (Clone BS66, BSH-7459, Nordic Biosite, T€aby, Sweden) and
Anti-Desmin mouse monoclonal antibody (Clone BS21, Nordic Bio-
site, T€aby, Sweden) were used to detect rat muscle tissue. Finally,
CD68 antibody 1:200 (Clone: ED1, ab31630, ABCAM, Cambridge,
United Kingdom) was used to detect rat macrophages and verify
the origin (PMP-50 containing hASCs or naturally iron containing rat
macrophages) of positive Perls Prussian blue staining. All antibodies
were produced in mouse and primary antibodies were detected
using anti-mouse horseradish peroxidase polymer. Rat and human
parafﬁn control multi-tissue sections were used as a negative and
positive tissue controls for immunohistochemical analyses.
Olympus BX-60 microscope (BSH 747) and an integrated color
digital camera (Scion) were used for the evaluation of the slides.
The slides were also imaged and digitalized with a 3D Histec Pan-
noramic MIDI instrument. The scoring of the inﬂammation was
based on the inﬂammatory cell inﬁltration into the lesion site,
edema, hemorrhage and necrosis of tissue [34]. The number of
inﬂammatory cells was evaluated manually from the low power
ﬁeld (3200) image frame using a “hot spot” selection. The inﬂam-
mation was scored with following grades: 05 no histological fea-
tures of inﬂammation; 15 diffuse inﬂammatory cell inﬁltration,
<100 cells; 25 diffuse inﬂammatory cell inﬁltration, 100–500
cells, mild edema and hemorrhage; 35 inﬂammatory cell inﬁltra-
tion, >500 cells, edema and hemorrhage; 45 inﬂammatory cell
inﬁltration, >1,000 cells, edema, hemorrhage and necrosis. Fibro-
sis was evaluated separately with following grades: 05 no ﬁbro-
sis; 15mild ﬁbrosis/collagen formation; 25 strong ﬁbrosis/
collagen formation. The inﬁltration of the cells into the hydrogel
was evaluated with samples containing Bulkamid.
Statistical Analysis
The statistical analysis was performed by using the IBM SPSS ver-
sion 22 (IBM, Chicago, IL, USA). The four treatment groups were
compared at baseline, at 2, and at 4 weeks. Statistical signiﬁcance
was tested by using chi-square or Fisher’s exact test with categori-
cal and one-way analysis of variance (ANOVA) with continuous
variables. The groups and the time points within the groups were
compared using ANOVA for repeated measures.
RESULTS
In Vitro Results
Live/dead staining demonstrated that after 3 hours of incubating
the hASCs in Bulkamid, the hASCs were mostly alive. However,
there were also some dead cells in the mixture (Fig. 2). The hASC
phenotype was assessed at passage 7 using ﬂow cytometry. The
hASCs expressed surface markers CD73 (99.9%), CD90 (99.9%),
and CD105 (99.6%). Expression of CD14 (1.4%), CD45RO (0.6%),
and HLA-DR (0.3%) was very low, and expression of CD19 (6.0%),
CD34 (8.1%), and CD54 (8.5%) was low. This conﬁrms the mesen-
chymal origin of the hASCs.
In Vivo Results
The baseline rat characteristics (weight, ARM measurements) of
each group are presented in Table 2. The rats in the 0.9% NaCl and
Bulkamid control groups were slightly, though statistically signiﬁ-
cantly, heavier than the hASC treatment groups’ rats. Otherwise,
there was no difference in baseline characteristics between the
groups.
Anorectal Manometry Results
First, the four groups were compared based on the ARM results
before injury and at 2 and 4 weeks. The measured variables were
the median resting pressure and the peak pressure during sponta-
neous contraction of the anal sphincter complex. The median rest-
ing and the peak contraction pressures were higher in the hASC
treatment groups at 2 and at 4 weeks (Table 2). Further analysis
showed that the trend of the contraction pressure was signiﬁ-
cantly higher in the both hASC-groups compared with the saline
and Bulkamid control groups (Fig. 3). The difference between the
groups remained statistically signiﬁcant when adjusted for base-
line measurement.
Histology
In the histological analysis, no hASCs were recognized in the prep-
arations neither at 2 nor 4 weeks according the Vimentin,
STEM121, or Perls Prussian blue staining. This was conﬁrmed with
CD68 staining of rat macrophages. Rat endogenous macrophages
containing iron stained positively with Perls Prussian blue and rat
speciﬁc CD68 immunoperoxidase reaction located into the same
cells (Fig. 4). Vimentin and STEM121 were positive in a cytoblock
section prepared from the same cells that were injected into the
rats (data not shown).
There was no statistical difference in sphincter muscle conti-
nuity, ﬁbrosis, or collagen formation between the four groups. The
Bulkamid-hydrogel was well integrated in the tissue with minor
foreign body reaction according to the HE staining. There was
more inﬂammation in the hASC-groups, especially in the 0.9%
NaCl 1hASC-group (Table 2; Fig. 4, Supporting Information Fig.
S2).
Figure 2. Live/dead staining of the human adipose stem cells in
Bulkamid; dead cells (red), live cells (green). Scale bar 1.0 mm.
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mCT Analysis
The mCT image datasets were used to conﬁrm independently the
continuity of the sphincter muscle shown in the histology. By
viewing the image data in multiple orthogonal views, greater con-
ﬁdence could be attested to the histological assessment. (Fig. 5,
Supporting Information video). There was total agreement
between histology and lCT interpretation in 76% of the samples.
There was minor disagreement in 11 samples and serious dis-
agreement in muscle continuity in 3 samples (5%). This did not
affect the statistical difference between the groups. Thus, the
ability to conduct nondestructive histomorphometric analysis on
samples provides valuable image data that can be used to perform
robust 3D analyses when necessary. In some samples with Bulka-
mid, small regions with high x-ray attenuation regions were
observed that could indicate cells or remains of PMP-50 particles
(data not shown). However, it was not possible to conﬁrm
whether these regions indicate the presence of PMP-50 particles
or whether they were the result of local aggregation of iodine. As
iron speciﬁc staining of the histological samples failed to detect
PMP-50 in any of the samples, the presence of PMP-50 particles
could not be conﬁrmed.
DISCUSSION
Our aim is to develop an effective, mini-invasive treatment for AI,
which is a highly distressing condition and all the more lacking an
efﬁcient treatment method. Studies about the existing treatment
methods are heterogeneous and long-term results are mostly
missing. Tissue engineering and cell therapy have been considered
to be compelling alternatives and hold a great deal of promise
and excitement. The advantage of using ASCs compared with the
other stem cell sources is that the tissue can easily be harvested
and it is readily available in large quantities. ASCs can be
easily expanded in vitro and have an extensive self-renewal
capacity [35, 36].
In our in vivo-study, we found signiﬁcant improvement in anal
sphincter resting and contraction pressures in hASC treatment
groups after acute sphincter injury compared with the control
groups. Previous functional anal sphincter assessments have
mostly been performed in vitro using anal sphincter muscle sam-
ples from euthanized animals to measure the contractility after
electrical stimulation [10, 12, 17, 37]. Salcedo et al. measured in
Figure 3. The trends of the four groups showed a signiﬁcantly
higher contraction pressures in both hASC treatment groups. Abbre-
viations: hASCs, human adipose stem cells; NaCl, sodium chloride.
Table 2. The rat baseline characteristics, functional results from anorectal manometry and histology
0.9%NaCl1 hASC Bulkamid1hASC 0.9%NaCl Bulkamid
Mean/median SD/Q1–Q3 Mean/median SD/Q1–Q3 Mean/median SD/Q1–Q3 Mean/median SD/Q1-Q3 p value
Weight (g) 268.0/
270.0
12.1/
260.0–280.0
263.6/
270.0
18.6/
250.0–280.0
275.4/
280.0
15.7/
267.5–290.0
285.3/
280.0
11.4/
280.0–300.0
.002
PreopARM (n) 15 14 14 15
Rest med 9.1 3.4 8.4 2.8 7.8 2.4 8.2 2.3 .640
Peak contr 97.5 25.2 88.5 29.6 81.3 22.1 85.0 23.3 .349
ARM 2 wk (n) 15 14 14 15
Rest med 9.3 2.6 9.6 2.1 4.9 3.2 5.2 1.6 < .000
Peak contr 74.6 16.0 74.0 13.6 44.6 20.6 47.8 14.3 < .000
ARM 4 wk (n) 8 8 8 9
Rest med 10.1 3.0 9.2 2.3 5.4 2.5 6.1 3.4 .005
Peak contr 79.5 16.4 76.2 21.3 52.4 27.2 46.6 26.7 .014
Inﬂammation .003
gr 0 (%) 0.0 21.4 28.6 33.3
gr 1 (%) 20.0 28.6 50.0 46.7
gr 2 (%) 40.0 42.9 21.4 20.0
gr 3 (%) 13.3 7.1 0.0 0.0
gr 4 (%) 26.7 0.0 0.0 0.0
Abbreviations: ARM 2 wk, anorectal manometry at 2-week time point; ARM 4 wk, anorectal manometry at 4-week time point; hASC, human adipose
stem cells; NaCl, sodium chloride; Peak contr, peak pressure during spontaneous contraction; Preop ARM, preoperative anorectal manometry; Q1–
Q3, 25 and 75 percentiles; Rest med, median resting anal pressure; Weight, preoperative weight.
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vivo function of the anal sphincter after a sphincterotomy or
pudendal nerve crush followed by either rat bone-marrow derived
MSC injection or saline [18]. In their further investigations, the
same research group found that both serial i.v. infusion and i.m.
injections of MSCs after partial sphincter excision resulted in
increased anal pressures [19]. Pathi et al., on the other hand, did
not ﬁnd signiﬁcant advantage in the iv-administration of rat bone-
marrow derived MSCs compared with the PBS controls, but the
local injections of MSCs were effective according to in vitro assess-
ment [17]. Recently Fitzwater et al. noticed that the administra-
tion of rat myogenic stem cells enhanced the contractile function
of the sphincter without signiﬁcant changes in histologic morphol-
ogy, which addresses the paracrine processes in stem cell therapy
[14]. To simplify the cell isolation and proliferation process, Maz-
zanti et al. used freshly isolated minimally manipulated bone-
marrow derived mononuclear cells without expansion and found
them to be as effective as in vitro expanded BM-MSCs in the
recovery of iatrogenic anal sphincter rupture [38]. Muscle-derived
stem cell injections have been used in small pilot studies in
women and the results are promising [39–41]. Frudinger et al.
treated 10 patients with autologous myogenic stem cells and
found a signiﬁcant improvement in the AI symptoms at 1- and
5-year controls. However, there was no signiﬁcant change in anal
manometry measurements [39, 40]. In a small pilot study, where
hASCs therapy was used in combination with surgical sphinctero-
plasty in treatment of AI, there was no difference in AI symptoms
Figure 4. The histology stainings and examples of the inﬂammatory grading. (A): Picosirius red-staining, 0.9% sodium chloride (NaCl) at 2
weeks; (B): Anti-Desmin, Bulkamid at 4 weeks; (C): Immunohistochemistry staining CD68, Bulkamid1hASC at 2 weeks; (D): HE-staining, Bulka-
mid1hASC at 2 weeks, inﬂammation grade 1; (E): HE-staining, Bulkamid1hASC at 4 weeks, inﬂammation grade 2; (F): HE-staining,
0.9%NaCl1 hASC at 2 weeks, inﬂammation grade 4; (G): Perls Prussian blue-staining for iron particles, Bulkamid1hASC at 2 weeks; (H): Com-
bination of CD68 and Perls Prussian blue of the sample G showing that the iron particles localize at the rat endogenous macrophages.
Arrow5 Bulkamid1hASC-injection. Scale bar Figures (A–F) 500 lm, Figures (G–H) 20 lm.
300 Adipose Stem Cells in Rat Anal Sphincter Injury
Oc 2018 The Authors STEM CELLS TRANSLATIONAL MEDICINE published by
Wiley Periodicals, Inc. on behalf of AlphaMed Press
STEM CELLS TRANSLATIONAL MEDICINE
between the hASC and saline injection group. However, the num-
ber of patients was limited and heterogeneous and the follow-up
time short. Despite these limitations, they discovered an increase
in total muscle area in an endorectal sonography assessment in
the hASC treatment group compared with the saline control group
[20].
In our study, the anal pressures were comparable with the
other animal studies although there are slight variations—possibly
due to different techniques (balloon vs. double-triple-lumen-
catheter, electrical stimulation vs. spontaneous contraction) and
different size of the anal canal in different species [13, 16, 19]. Sal-
cedo et al. stated that rat anal pressures tend to return to baseline
after sphincterotomy at 4 weeks even without intervention, but
this does not occur after pudendal nerve transection [42]. In our
results, both resting and contraction anal pressures were signiﬁ-
cantly lower in both control groups at 2 and 4 weeks compared
with the hASC treatment groups. There was also a rising pressure
trend within the stem cell groups that might have resulted in even
higher pressures and better recovery in longer follow-up.
We used ASCs from a single donor mainly because of the
safety regulations. It is known that there is some heterogeneity
between different donors; for example, age, sex, body mass index,
and site of harvest are known to have an effect on the properties
of the ASCs [43–47]. Xenotransplantation has been used before to
study development, physiology, and pathophysiology of human
tissues in animal models, for example, enteric nervous system [48]
and rodent models have been tested in treatment of stroke [49]
and myocardial infarct [50]. However, there are differences in
human and animal physiology that have to be kept in mind when
interpreting the results [51].
Different labeling systems of injected cells have been used in
previous studies. Kang et al. found ﬂuorescent dye PKH-26 labeled
rat myogenic stem cells in ﬂuorescent microscopy of rat anal
sphincters at one week after the injection [10]. PKH-26 label in
animal autologous myogenic stem cells were also used by Kajbaf-
zadeh (rabbit) and Oh (dog): both groups found labeled cells at
2 months and 3 months control, respectively [15, 16]. Aghaee-
asfhar et al. used bromodeoxyuridine labeled human umbilical
cord stem cells as well as rabbit bone marrow stem cells (BMSCs)
in a rabbit model, the labeled cells were found in immunohisto-
chemistry at 2 weeks control [52]. On the other hand, Cruz et al.
demonstrated that the green ﬂuorescent protein (GFP) labeled rat
BMSCs disappear in 10 days after i.v.-administration [53]. Salcedo
et al. found no visible GFP-labels in the anal sphincter after admin-
istration of i.m. or i.v. MSCs derived from rat bone marrow [18].
We attempted to ﬁnd the PMP-50 labeled hASCs in the tissue
samples using mCT, histology and immunohistochemistry.
Although some potential signs of PMP-50 were detected in mCT,
we were not able to conﬁrm the PMP-50 labeled cells either in
the mCT scan or in the histology analysis. Histological sections
stained positive with Perls Prussian blue but rat macrophage spe-
ciﬁc CD68 antibody stained the same cells indicating that the sig-
nal comes from hASCs ingested by rat macrophages or just iron
that macrophages contain naturally. In our pilot study, there were
tracks of the injected cells in hydrogel with the higher cell amount
(5 3 106 cells/100 ll) and with bigger injection volume 100 ll
(Supporting Information Fig. S2). In the actual study, due to better
cell viability and injection experience, we decided to use lower
cell count and lower volume and were not able to verify the pres-
ence of the stem cells. The evanescence of the cells may be due to
the rat immune defense destroying the human cells. This is sup-
ported by the lack of human speciﬁc STEM121 and Vimentin stain-
ing of the tissue sections.
There are also the safety considerations in cell therapy. Jacobs
et al. found no evidence of myogenic stem cell migration to the
liver or lung. However, they detected local ectopic foci of growth
in two treated rat anal sphincters after 30 days; the small tumors
were benign tumors with no nuclear abnormalities [54]. In our
study, normal histology was conﬁrmed both by 3D mCT scanning
of the whole sphincter sample area, as well as by selected histo-
logical sections. The lCT is a valuable approach to visualize the
entire treated area and the injection sites in 3D to target the histo-
logical slides. The ability to increase imaging resolution without
proportionally decreasing sample size opens possibilities for per-
forming analyses without destructive sample preparation. The mCT
protocol applied in this study showcased this methodology by
complementing the traditional histological analyses with
increased amount of available data, which resulted in greater con-
ﬁdence in the analysis. Additionally, in combination with appropri-
ate concentrations of labeling agents, it may also be feasible to
monitor the distribution of introduced cells.
This animal model, like any other animal model, is not directly
comparable with birth injury in humans. The trauma in the rat
model was caused by a direct clean-cut wound whereas in
Figure 5. Comparison of the micro-computed tomography (A) and histology (B) images. Arrow5 injected Bukamid hydrogel.
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obstetric trauma the sphincter is torn, and the tissue has suffered
from prolonged hypoxia and denervation. In an obstetric trauma,
there is also presence of tissue edema and blood, which makes
suturing the rupture more challenging in real life. In our animal
model, the rupture was easy to identify with no delay, and the
operative technique was consistent with only one operator. The
small scale of the rat anatomy made it difﬁcult to distinguish the
inner and outer sphincter from each other and that is why the
injections were aimed at the external sphincter rather than sub-
mucosa or between the sphincters. In humans, the intersphinc-
teric injection might be better. However, our model applies to
acute injury and is perhaps not applicable for chronic conditions
with ﬁbrous anal sphincters often seen in AI patients. Fibrosis is a
histological ﬁnding often seen in scar tissue and in our model the
follow up time was too short to analyze the possible impact on
scar tissue formation. There is evidence that cell therapy might be
able to prevent vocal fold scaring in laryngeal microsurgery and
ﬁbrous keloid formation after skin incision in acute trauma model
[55, 56].
The possible mechanisms of AI stem cell therapy are direct
stem cell integration and muscle regeneration, the bulking effect
of the cells and the carrier, the trophic effect caused by the stem
cell growth factor secretion or immune modulation, and the
decreased inﬂammation that improves tissue healing [33, 57]. The
bulking effect is probably not the mechanism according to our
results, because there was no advantage in the bulking agent Bul-
kamid compared with the 0.9% NaCl-controls, and also because
there were good results with hASCs in 0.9% NaCl as well. For
human AI, the bulking effect in the injection therapy is perhaps
not even desirable [58]. According to our results, lack of differen-
ces in muscle continuity between the groups refers to paracrine
effect rather than to direct stem cell differentiation into muscle
cells. The mechanism may be through cell fusion, endogenous
activation of satellite cells or some inﬂammatory process [59].
From the inﬂammatory perspective, Bulkamid seems to have an
advantage over 0.9% NaCl as a carrier, although it is not clear
what stage of inﬂammation is desirable for the healing process.
Bisson et al. showed that certain amount of inﬂammation and
acute injury is required in cell therapy: injection of myoblasts on
the opposite site of cryoinjured anal sphincter did not restore the
anal sphincter function, whereas the injection into the lesion itself
did [60]. On the other hand, Salcedo et al. showed that systemic
injection also had a positive effect; however, this was not seen in
the study of Pathi et al. [17, 19]. One advantage of hydrogel over
0.9% NaCl is that the cell sedimentation and aggregation are
mostly avoided with Bulkamid. Bovine collagen gel (Contigen) has
also been used in clinical trials experimenting stem cell injection
therapy for female urinary incontinence [61, 62].
It has been suggested that stem cell transplantation may facili-
tate endogenous repair even in patients with advanced age and
comorbidities who have compromised repair function [13]. There-
fore, stem cell therapy would be especially useful in patients with
compromised anal sphincter function. Bohl et al. have successfully
implanted engineered biosphincters in rabbits with iatrogenic AI
to restore anal sphincter function [63]. Sphincter transplantation
is however a major surgical operation. Stem cell injection therapy
can be performed under local anesthesia in an outpatient setting
with no major complications. According to our preliminary results,
the ASC treatment is effective in treatment of an acute anal
sphincter injury. In the future, animal models for chronic injury are
needed to develop an effective and clinically relevant treatment
method.
CONCLUSION
ASCs combined with either saline or synthetic nondegradable
hydrogel is a novel and attractive, mini-invasive treatment
method for acute anal sphincter rupture and AI. Due to low
inﬂammatory response and good tissue integration, Bulkamid
hydrogel appears to be a suitable injection agent and carrier for
the ASCs. The technique of anal sphincter injection therapy is sim-
ple in an animal setting and the use of human ASCs in rat AI
model is feasible. The 3D lCT is a valuable addition to the tradi-
tional histology in analyzing soft tissue samples. Further studies
with suitable chronic injury animal models with longer follow-up
periods are needed to conﬁrm the functional restoration and to
develop a truly effective treatment method for AI patients.
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